e-Edition
Obituaries
Special Sections
Special Occasions
Contact

Subscribe
Paywall Login
Login to Comment
Register

December 11th, 2017

jobs

homes

Home
News
Sports
Business
Entertainment
Classifieds
Commentary

Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Neurocrine Biosciences, Inc. - Common Stock (NQ:NBIX)

129.86 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EDT, Mar 10, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Neurocrine Biosciences, Inc. - Common Stock

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

Benzinga's Top Ratings Upgrades, Downgrades For February 25, 2022 ↗

February 25, 2022

Upgrades According to 86 Research, the prior rating for NetEase Inc (NASDAQ:NTES) was changed from Hold to Buy. For the fourth quarter, NetEase had an EPS of $1.56,...

Via Benzinga

Looking Into Neurocrine Biosciences's Return On Capital Employed ↗

February 14, 2022

Benzinga Pro data, Neurocrine Biosciences (NASDAQ:NBIX) reported Q4 sales of $312.00 million. Earnings fell to a loss of $7.30 million, resulting in a 132.44% decrease from last quarter.

Via Benzinga

Why Neurocrine Biosciences Are Trading Higher Today? ↗

February 11, 2022

Neurocrine Biosciences Inc (NASDAQ: NBIX) reported Q4 Ingrezza sales of $301 million, +25% Y/Y, with total prescriptions up 32% Overall sales increased $312.0 million...

Via Benzinga

Analyst Ratings For Neurocrine Biosciences ↗

February 01, 2022

Within the last quarter, Neurocrine Biosciences (NASDAQ:NBIX) has observed the following analyst ratings:

Via Benzinga

The Daily Biotech Pulse: Adcom Recommends Additional Trials For Lilly's Partnered Cancer Drug, Novavax Touts Pediatric Vaccine Data, TC Biopharm IPO ↗

February 11, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Adcom Rules That Lilly May Have To Conduct Additional Studies For Co-...

Via Benzinga

Recap: Neurocrine Biosciences Q4 Earnings ↗

February 11, 2022

Neurocrine Biosciences (NASDAQ:NBIX) reported its Q4 earnings results on Friday, February 11, 2022 at 07:30 AM. Here's what investors need to know about the announcement. Earnings Neurocrine...

Via Benzinga

Earnings Scheduled For February 11, 2022 ↗

February 11, 2022

Companies Reporting Before The Bell • Mr. Cooper Group (NASDAQ:COOP) is expected to report quarterly earnings at $1.22 per share on revenue of $551.60 million.

Via Benzinga

A Preview Of Neurocrine Biosciences's Earnings ↗

February 10, 2022

Neurocrine Biosciences (NASDAQ:NBIX) is set to give its latest quarterly earnings report on Friday, 2022-02-11. Here's what investors need to know before the announcement. Analysts estimate that...

Via Benzinga

The Week Ahead In Biotech (Feb. 6-12): Pfizer, AstraZeneca Earnings, Conference Presentations, IPOs And More ↗

February 06, 2022

Biotech stocks managed to close the week ending Feb. 4 with gains. Stocks recovered along with the broader markets early in the week, but came under pressure midweek amid negative reaction to some big...

Via Benzinga

10 Biggest Price Target Changes For Tuesday ↗

January 18, 2022

Keybanc raised J.B. Hunt Transport Services, Inc. (NASDAQ:

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For January 18, 2022 ↗

January 18, 2022

Upgrades Canaccord Genuity upgraded the previous rating for Fortuna Silver Mines Inc (NYSE:

Via Benzinga

Xenon Receives $15M Regulatory Milestone Under Epilepsy Pact With Neurocrine ↗

January 12, 2022

Xenon Pharmaceuticals Inc's (NASDAQ: XENE) collaboration to develop treatments for epilepsy with Neurocrine Biosciences Inc (NASDAQ: NBIX) achieved a regulatory...

Via Benzinga

Analyst Ratings For Neurocrine Biosciences ↗

January 07, 2022

Over the past 3 months, 9 analysts have published their opinion on Neurocrine Biosciences (NASDAQ:

Via Benzinga

The Daily Biotech Pulse: Glaukos Gets FDA Nod, Neurocrine Preannounces Soft Ingrezza Sales, 3 IPOs ↗

January 07, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Hepion's Lead NASH Drug Candidate Gets The Non-Proprietary Name...

Via Benzinga

Expert Ratings For Neurocrine Biosciences ↗

December 08, 2021

Neurocrine Biosciences (NASDAQ:NBIX) has observed the following analyst rat...

Via Benzinga

The Daily Biotech Pulse: Valneva Strikes Deal To Supply COVID Vaccine to Bahrain, TherapeuticsMD & Amneal Settle Patent Lawsuit, Reata Awaits Adcom ↗

December 08, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus EyePoint Announces Commercialization Agreement For Dexycu To Treat Post-...

Via Benzinga

Topics Intellectual Property Lawsuit

Neurocrine's Ingrezza Meets Primary Goal In Phase 3 Study In Patients With Involuntary Muscle Movement ↗

December 08, 2021

Neurocrine Biosciences Inc (NASDAQ: NBIX) revealed topline data from its Phase 3 KINECT-HD study evaluating Ingrezza (valbenazine) for chorea associated with...

Via Benzinga

Neurocrine Pens $2.6B Pact With Sosei Heptares For Neuro Targets ↗

November 22, 2021

Neurocrine Biosciences Inc (NASDAQ: NBIX) has outlined a deal that provides Sosei Heptares Corporation $100 million upfront, R&D expenses, and a...

Via Benzinga

Mobile Mental Health: Coming to a Home Near You? ↗

November 18, 2021

Photo by Anna Shvets from Pexels The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial...

Via Benzinga

Analyst Ratings For Neurocrine Biosciences ↗

November 17, 2021

Neurocrine Biosciences (NASDAQ:NBIX) has observed the following analyst rat...

Via Benzinga

Why Neurocrine Biosciences Shares Fell Nearly 10% Today ↗

November 02, 2021

Investors have grown weary of unpredictable profitability and unexpected expenses.

Via The Motley Fool

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

November 02, 2021

Gainers Kiniksa Pharmaceuticals (NASDAQ:KNSA) stock increased by 16.73% to $14.86 during Tuesday's regular session. The current volume of 1.0 million shares is 269.7%...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For November 19, 2021 ↗

November 19, 2021

Upgrades Morgan Stanley upgraded the previous rating for EQT Corp (NYSE:

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For November 17, 2021 ↗

November 17, 2021

Upgrades According to Williams Capital, the prior rating for On Holding AG (NYSE:

Via Benzinga

What 5 Analyst Ratings Have To Say About Neurocrine Biosciences ↗

November 02, 2021

Over the past 3 months, 5 analysts have published their opinion on Neurocrine Biosciences (NASDAQ:

Via Benzinga

71 Biggest Movers From Yesterday ↗

November 03, 2021

Gainers Avis Budget Group, Inc. (NASDAQ: CAR) shares climbed 108.3% to close at $357.17 on Tuesday after the company reported better-than-expected Q3 adjusted EPS and sales...

Via Benzinga

The Daily Biotech Pulse: Pfizer Reports Solid Q3 Earnings, Regulatory Setback For Legend, Lilly to Supply Additional COVID-19 Antibody Cocktails To US ↗

November 02, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus SAB Spikes On Analyst Action SAB Biotherapeutics, Inc. (NASDAQ: SABS) shares...

Via Benzinga

Neurocrine Biosciences, Inc (NBIX) Q3 2021 Earnings Call Transcript ↗

November 01, 2021

NBIX earnings call for the period ending September 30, 2021.

Via The Motley Fool

Topics Earnings

12 Health Care Stocks Moving In Monday's After-Market Session ↗

November 01, 2021

Gainers Biophytis (NASDAQ:BPTS) shares mo...

Via Benzinga

Neurocrine Biosciences: Q3 Earnings Insights ↗

November 01, 2021

Neurocrine Biosciences (NASDAQ:NBIX) reported its Q3 earnings results on Monday, November 1, 2021 at 04:01 PM. Here's what investors need to know about the announcement....

Via Benzinga

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

More ways to get to us

Facebook

Twitter

YouTube

ePaper Login
Subscribe
Subscription Services
Archive

About Us

The Lethbridge Herald
Other Publications
Food For Thought

Contact
Careers

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

Advertising
Terms and Conditions & Privacy Policy